RNS Number:5780O
Henderson Morley PLC
12 August 2003


FOR IMMEDIATE RELEASE                                      12 AUGUST 2002



                              HENDERSON MORLEY PLC                                          
                                      (AIM)
                                        
                                        
                            Business: Drug Discovery
                                        
                                        
                RESULT OF AGM AND CHAIRMAN'S ADDITIONAL REMARKS
                                        

The Board of Henderson Morley plc ("Henderson Morley" or "the Company")
announces that at the Company's Annual General Meeting held earlier today, all
the resolutions were duly passed.


Chairman, Andrew Knight, commented: "As I stated in my Chairman's Statement,
this year has been particularly exciting for Henderson Morley as the company
concluded its first product out-licence. We have now received the first report
from Croma Pharma, following their initial (Phase I) work on the ocular
application of ICVT, and I would like to give you some extracts from that
report.


"Croma have successfully completed this initial phase using 12 healthy
volunteers with a preparation applied 6 times daily and, in their opinion, the
results achieved demonstrated the safety of the formulation."


Dr Clausen, Head of the Clinical Project Team for Croma, said: "Our optimistic
planning of the initial phase was beaten by the results of the study. Now I am
looking forward, with great pleasure and optimism, to the start of Phase II. I
am convinced that the therapy will be a success. This will give us the
possibility to bring a safe therapy to a broad mass of patients in future.


"Croma expect the Phase II study to be approved by the Ethics Committee by the
end of October 2003.


"We are very pleased at the progress being made by Croma and are continuing to
seek partners for the other applications of ICVT and will report on this at the
appropriate time."



                                      ENDS



Copies of this announcement will be available free of charge to the public at
the Company's registered office at Metropolitan House, 2 Salisbury Road,
Moseley, Birmingham, B13 8JS and at the offices of Brewin Dolphin Securities
Ltd, 34 Lisbon Street, Leeds LS1 4LX for 14 days.



Enquiries:

HENDERSON MORLEY PLC                                         Tel: 0121 442 4600
Andrew Knight, Chairman

BREWIN DOLPHIN SECURITIES LTD                                Tel: 0113 241 0126
Neil Baldwin

BARNES AND WALTERS LTD                                       Tel: 020 7430 1600
Maxine Barnes                                              Mobile 07860  489571           

                                                     








                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
RAGSFIFEESDSESA